On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Achieves Important Milestones in Fight against Advanced Breast Cancer

  • New, frozen formulation of ready-to-inject Bria-IMT increases potency, simplifies logistics and is expected to reduce cost-per-dose
  • BriaCell has achieved proof of concept for its lead cellular immunotherapy product, Bria-IMT, which targets advanced breast cancer
  • Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit in Paris on March 21-22

Researchers at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer, are noting significant advancements in clinical trials of the company’s lead cellular immunotherapy product, Bria-IMT, targeting advanced breast cancer.

“It’s been a very, very exciting time at BriaCell. In 2018, we achieved a number of important milestones. We achieved proof of concept for our lead clinical candidate, Bria-IMT,” BriaCell president and CEO Dr. Bill Williams states in an interview with NetworkNewsWire (http://nnw.fm/eo7BC) that describes the large unmet medical needs of advanced breast cancer and the market opportunity that they present.

The American Cancer Society (“ACS”) estimates that in 2019 there will be an estimated 1,762,450 new cancer cases diagnosed, which is the equivalent of more than 4,800 new cases each day. Of these overall cases, there will be approximately 268,600 new cases of female breast cancer, accounting for 30 percent of all new cancer diagnoses in women, as the ACS detailed in its latest report on cancer statistics (http://nnw.fm/COpZ3).

Perhaps more alarming is a new study showing that the number of women in the U.S. living with distant metastatic breast cancer (“MBC”), the most severe form of the disease, is growing. The researchers estimated that, as of January 1, 2017, more than 150,000 women in this country were living with MBC, and that three in four of them had initially been diagnosed with an earlier stage of breast cancer. The findings appeared online in Cancer Epidemiology, Biomarkers & Prevention and is also published on the National Cancer Institute’s website (http://nnw.fm/jj9R3).

BriaCell is focused on enhancing the lives of cancer patients who are facing limited therapeutic options. Designed by a team of scientists and clinicians, BriaCell’s proprietary whole-cell-based technology platform continues to show its impressive potential to establish a new model for treating cancer patients.

Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. Bria-IMT has shown promise in FDA-approved clinical trials, suggesting excellent safety and efficacy in patients who match Bria-IMT at HLA types. BriaCell also recently announced the initiation of clinical use of a novel frozen formulation of Bria-IMT for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs (http://nnw.fm/160Iu).

“We’re going full barrel, full force into 2019,” Williams states in the NNW interview (http://nnw.fm/xCvB7). “We have ongoing discussions with multiple potential partners to form some corporate partnerships, and we’re very optimistic about those. We have preliminary efficacy data coming out on our first six patients in the KEYTRUDA combination study, and then we have multiple opportunities to present at conferences to get the word out there.”

BriaCell continues to gather new insights on completed studies as immune responses and test results are further analyzed, which includes noting “exciting information” about the company’s ongoing combination study with KEYTRUDA that will be shared at upcoming oncology conferences.

BriaCell Founder and Director Dr. Charles L. Wiseman will be a keynote speaker at the 10th Euro Breast Cancer Summit, taking place in Paris on March 21-22, 2019. The summit’s theme for 2019 is rediscovering novel approaches toward a cure for breast cancer and women’s health (http://nnw.fm/fP8Bq). Wiseman’s topic is aptly titled ‘Targeted Immunotherapy for Breast Cancer – Immunotherapy – Fact, myths and experience: Myth Busters: How beautiful facts can falsify ugly theories’.

For more information, visit the company’s website at www.BriaCell.com

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office


Select A Month

Contact us: 212.418.1217